Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis
Received Date : 13 Jan 2023
Accepted Date : 28 Feb 2023
Available Online : 10 Mar 2023
Doi: 10.37047/jos.2023-95447 - Article's Language: EN
J Oncol Sci. 2023;9(1):38-45
This is an open access article under the CC BY-NC-ND license
Objective: This study aimed to investigate the effectiveness of first-line treatments and survival-related prognostic factors in castration- resistant prostate cancer (CRPC) with isolated bone metastasis. Material and Methods: Clinicopathological characteristics of patients diagnosed with CRPC and isolated bone metastasis presenting to the Medical Oncology Clinic of Dicle University between January 2010 and December 2020, as well as the treatments received by them, were retrospectively evaluated. Results: Our study included 91 prostate cancer patients that were in the castration-resistant stage and had isolated bone metastases. As the first-line treatment, 43 (47.2%) of our patients received docetaxel (DOC), 27 (29.6%) received abiraterone acetate (AA), and 21 (23.2%) received enzalutamide (ENZA). The median progression- free survival (PFS) periods for the DOC, AA, and ENZA groups were 9 months [95% confidence interval (CI): 6.52-11.47], 8 months (95% CI: 3.54-12.45), and 13 months (95% CI: 8.09-17.90), respectively (p=0.047). The median overall survival (OS) periods among patients receiving DOC, AA, and ENZA during the hormone-refractory period were 13 months (95% CI: 8.48-17.51), 12 months (95% CI: 8.58- 15.41), and 20 months (95% CI: 2.90-37.09), respectively (p=0.13). Multivariate analyses indicated that the choice of first-line treatment received by the patients was an independent prognostic factor for PFS, whereas lymph node metastasis was an important prognostic variable for OS. Conclusion: Our study involving CRPC patients with isolated bone metastases demonstrates similar OS among patients receiving DOC, ENZA, or AA as the first-line treatment for prostate cancer, although ENZA is associated with a better PFS.
  1. Ferlay J, Colombet M,Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40countries and 25 major cancers in 2018. Eur J Cancer. Nov 2018;103:356-387. [Crossref]  [PubMed] 
  2. Steele CB, Li J, Huang B, Weir HK.Prostate cancer survival in the United States by race and stage (2001-2009): Findings fromthe CONCORD-2 study. Cancer. 2017;123 Suppl 24(Suppl 24):5160-5177. [Crossref]  [PubMed]  [PMC] 
  3. Pienta KJ, Bradley D. Mechanismsunderlying the development of androgen-independent prostate cancer. Clin Cancer Res.2006;12(6):1665-1671. [Crossref]  [PubMed] 
  4. Halabi S, Lin CY, Kelly WK, et al.Updated prognostic model for predicting overall survival in first-line chemotherapy forpatients with metastatic castration-resistant prostate cancer. J Clin Oncol.2014;32(7):671-677. Erratum in: J Clin Oncol. 2014;32(13):1387. [Crossref]  [PubMed]  [PMC] 
  5. Nuhn P, De Bono JS, Fizazi K, etal. Update on systemic prostate cancer therapies: management of metastaticcastration-resistant prostate cancer in the era of precision oncology. Eur Urol.2019;75(1):88-99. [Crossref]  [PubMed] 
  6. Ryan CJ, Smith MR, Fizazi K, etal; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plusprednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302): final overall survival analysis of a randomised, double-blind,placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-160. [Crossref]  [PubMed] 
  7. Ryan CJ, Smith MR, de Bono JS, etal; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previouschemotherapy. N Engl J Med. 2013;368(2):138-148. Erratum in: N Engl J Med. 2013;368(6):584. [Crossref]  [PubMed]  [PMC] 
  8. Tran C, Ouk S, Clegg NJ, et al.Development of a second-generation antiandrogen for treatment of advanced prostate cancer.Science. 2009;324(5928):787-790. [Crossref]  [PubMed]  [PMC] 
  9. Scher HI, Fizazi K, Saad F, et al;AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer afterchemotherapy. N Engl J Med. 2012;367(13):1187-1197. [Crossref]  [PubMed] 
  10. Beer TM, Armstrong AJ, Rathkopf DE, et al; PREVAIL Investigators.Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med.2014;371(5):424-433. [PubMed]  [PMC] 
  11. Halabi S, Kelly WK, Zhou H, etal. The site of visceral metastases (mets) to predict overall survival (OS) incastration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phaseIII trials. J Clin Oncol. 2014;32(suppl 15):5002. [Crossref] 
  12. Cui PF, Cong XF, Gao F, et al.Prognostic factors for overall survival in prostate cancer patients with differentsite-specific visceral metastases: A study of 1358 patients. World J Clin Cases.2020;8(1):54-67. [Crossref]  [PubMed]  [PMC] 
  13. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact ofsite of metastasis on overall survival in men with castration-resistant prostate cancer. JClin Oncol. 2016;34(14):1652-1659. [PubMed]  [PMC] 
  14. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men withmetastatic castration-resistant prostate cancer:American Society of Clinical Oncology andCancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-3448. [PubMed]  [PMC] 
  15. Lorente D, Mateo J, Perez-LopezR, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer.Lancet Oncol. 2015;16(6):e279-292. [Crossref]  [PubMed] 
  16. Hair JF, Black WC, Babin BJ, Anderson RE. Multivariate Data Analysis.7th ed. New York, USA: Pearson; 2010.
  17. Scosyrev E, Messing EM, Mohile S,Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease atpresentation and disease-specific mortality. Cancer. 2012;118(12):3062-3070. [Crossref]  [PubMed] 
  18. Shelke AR, Mohile SG. Treatingprostate cancer in elderly men: how does aging affect the outcome? Curr Treat Options Oncol.2011;12(3):263-275. [Crossref]  [PubMed] 
  19. Mandel P, Kriegmair MC, KamphakeJK, et al. Tumor characteristics and oncologic outcome after radical prostatectomy in men 75years old or older. J Urol. 2016;196(1):89-94. [Crossref]  [PubMed] 
  20. Tosoian JJ, Alam R, Gergis C, etal. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressivedisease. Prostate Cancer Prostatic Dis. 2017;20(2):193-196. [Crossref]  [PubMed]  [PMC] 
  21. Ingrosso G, Detti B, Scartoni D,et al. Current therapeutic options in metastatic castration-resistant prostate cancer. SeminOncol. 2018;45(5-6):303-315. [Crossref]  [PubMed] 
  22. Pond GR, Sonpavde G, de Wit R,Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site inmen with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65(1):3-6. [Crossref]  [PubMed] 
  23. Berthold DR, Pond GR, Soban F, deWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisonefor advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol.2008;26(2):242-245. [Crossref]  [PubMed] 
  24. Evans CP, Higano CS, Keane T, etal The PREVAIL study: primary outcomes by site and extent of baseline disease forenzalutamide-treated men with chemotherapy-naïve metastatic castration-resistant prostatecancer. Eur Urol. 2016;70(4):675-683. [Crossref]  [PubMed] 
  25. Zheng H, Chen J, Qiu W, et al.Safety and efficacy of first-line treatments for chemotherapy-naive metastaticcastration-resistant prostate cancer: a systematic review and indirect comparison. BiomedRes Int. Dec 2017;2017:3941217. [Crossref]  [PubMed]  [PMC] 
  26. Poon DMC, Chan K, Lee SH, et al;Hong Kong Society of Uro-Oncology (HKSUO). Differences in clinical outcome between docetaxeland abiraterone acetate as the first-line treatment in chemo-naïve metastaticcastration-resistant prostate cancer patients with or without the ineligible clinicalfactors of the COU-AA-302 study. Prostate Int. 2018;6(1):24-30. [Crossref]  [PubMed]  [PMC] 
  27. Zhang W, Wu TY, Chen Q, et al.Indirect comparison between abiraterone acetate and enzalutamide for the treatment ofmetastatic castration-resistant prostate cancer: a systematic review. Asian J Androl.2017;19(2):196-202. [Crossref]  [PubMed]  [PMC] 
  28. Saad F, de Bono J, Shore N, etaI. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.Eur Urol. 2015;67(2):223-230. [Crossref]  [PubMed] 
  29. de Bono JS, Smith MR, Saad F, etal. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patientswith metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. EurUrol. 2017;71(4):656-664. [Crossref]  [PubMed]  [PMC] 
  30. Siemens DR, Klotz L, HeidenreichA, et al. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patientswith Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. J Urol.2018;199(1):147-154. [Crossref]  [PubMed] 
  31. Afriansyah A, Hamid ARAH, MochtarCA, Umbas R. Prostate specific antigen (PSA) kinetic as a prognostic factor in metastaticprostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.F1000Res. Feb 2018;7:246. [Crossref]  [PubMed]  [PMC] 
  32. Mukherji D, Pezaro CJ,Shamseddine A, De Bono JS. New treatment developments applied to elderly patients withadvanced prostate cancer. Cancer Treat Rev. 2013;39(6):578-583. [Crossref]  [PubMed] 
  33. Miller K, Carles J, Gschwend JE,Van Poppel H, Diels J, Brookman-May SD. The phase 3 COU-AA-302 study of abiraterone acetateplus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostatecancer: stratified analysis based on pain, prostate-specific antigen, and gleason score. EurUrol. 2018;74(1):17-23. [Crossref]  [PubMed]